



# Consultations

## Consultation on the draft 2025/26 Invitation to Tender (for public input)

30 July 2025

### What we're proposing

Pharmac | Te Pātaka Whaioranga is seeking feedback from consumers, whānau, patient support groups, consumer advocacy groups, the public, and other interested people on the draft 2025/26 Invitation to Tender.

**Consultation closes at 4 pm (New Zealand standard time) on Monday 10 September 2025.**

**Submit feedback through our [online form](#) or email [tenderconsult@pharmac.govt.nz](mailto:tenderconsult@pharmac.govt.nz)**

We're particularly interested in feedback on the following questions:

- Would changing the brand of any of the medicines be inappropriate, and why?
- Are there any features of the medicines that we should consider when evaluating them, for example pack sizes?
- What would be the key issues for Pharmac to consider if there was a change in funded brand for any of the medicines?
- If funding restrictions (such as Special Authority criteria) were removed, what potential benefits, issues, or consequences could occur?
- Are there any groups of people where it would be clinically inappropriate, or more difficult, to undergo a brand change for a particular medicine? If yes, please provide detail.
- Are the proposed Additional Special Terms for intra-uterine devices [non-hormonal] (IUDs) appropriate?

- For intra-uterine devices [non-hormonal] (IUDs), we are considering making a MDR certification a mandatory requirement, rather than a preference. What are the potential issues, benefits or consequences of this change?

We welcome any other feedback you may give. You can contact us if you wish to meet to discuss anything in this consultation.

We are also seeking feedback from healthcare professionals and suppliers.

- [Healthcare professionals' consultation](#)
- [Suppliers' consultation](#)

Please share this consultation with others who you think might be interested. We want to hear feedback from a range of people.

## What would change?

As a result of the annual tender, your medicine may:

- change from one brand to another
- change from multiple brands to a single brand
- not change brand
- become available to more people

We introduce any brand changes over time, usually five months. The new brand will then be in place for at least 3 years.

## One brand may not fit all

Most people will start on, or move to, any new brand easily. However, we understand that people's experiences when taking medicines can be different.

In addition to clinical advice, we use our consultation on the draft tender to find out if we might need more options for some medicines. We can use an "alternative brand allowance" (ABA) to support people who may experience, or are at greater risk of, negative outcomes from a brand change.

This consultation is a chance to provide feedback on whether we should allow:

- people to move back to the old brand after bad side effects
- more time to change brands
- some patients to avoid switching altogether.

## New round of consultation

For last year's invitation to tender, Pharmac introduced an extra consultation step after the tender had closed, in addition to this consultation prior to the tender being issued. The additional consultation was for medicines where, after looking at the bids, we were considering a brand change. This is intended to help us better understand what a brand change could mean to people and how we could best support any change.

We did two consultations:

- [28 May 2025 | Consultation on possible brand changes through the annual tender](#)
- [8 July 2025 | Second consultation on possible brand changes through the annual tender July 2025](#)

This additional consultation step will be incorporated into the 2025/26 annual Invitation to Tender process and for future tenders.

## Is my medicine in the tender list?

**Schedule two: Products to be tendered (draft, by therapeutic group)** lists the medicines that we are proposing to include in this year's tender. Medicines have been grouped according to the therapeutic group classification system used in the Pharmaceutical Schedule.

A therapeutic group is a category that includes medicines used to treat similar health problems.

Below is a list of these groups, and the corresponding page numbers. Medicines that may treat multiple health problems only appear in one group.

Therapeutic group	Pages
Alimentary Tract and Metabolism (digestive issues and metabolic disorders)	8 - 9
Blood and Blood Forming Organs (disorders that affect blood and its components)	9
Cardiovascular System (heart and blood vessel conditions)	10 - 13
Dermatologicals (skin conditions)	13 - 15
Genito-Urinary System (urinary and reproductive system issues)	15
Hormone Preparations (conditions requiring regulation or replacement of hormones)	15 - 16
Infections (bacterial and other infections)	16 - 18
Musculoskeletal System (conditions affecting bones, muscles and joints)	18
Nervous System (includes analgesics, anaesthetics, neurological conditions, mental health, and dementia)	19 - 22
Oncology and Immunosuppressants (cancer)	22 - 23
Respiratory (lung conditions and allergies)	23
Sensory Organs (eye and ear conditions)	23

If you are unsure of the chemical name or therapeutic group for your brand of medicine, you can search the brand in the Pharmaceutical Schedule.

[Search the Pharmaceutical Schedule](#)

## About the annual tender

### Why does Pharmac run the tender?

Pharmac uses the tender to make sure medicines continue to be supplied and to create savings. Pharmac uses any savings to fund new medicines.

### What is the result of the tender?

If we award a tender for a medicine to a pharmaceutical supplier, then that supplier's brand becomes the main funded brand of that medicine. It would likely be the only brand of that medicine funded on the Pharmaceutical Schedule. We call this "Principal Supply Status". For this tender round, Principal Supply Status would be in place until June 2028.

If the brand awarded the tender was already the only funded brand, there would be no noticeable difference for most people, although the cost to the government's medicines budget may change.

### Which medicines are included in the tender?

Each year, Pharmac runs a tender that includes some of the medicines on the Pharmaceutical Schedule (the list of funded medicines). The list of medicines changes from year to year. Typically, medicines are tendered every three years.

Most medicines in the annual tender are already funded in New Zealand and are no longer under patent. A patent lets the inventor of a medicine own it exclusively for a set period – when that period ends, other suppliers can then make and sell that medicine.

### Who does Pharmac talk to about the tender?

Before we run the tender each year, we ask for feedback from healthcare professionals, consumer groups, the pharmaceutical industry, and the public. This can tell us if:

- tendering is appropriate for each medicine
- there are any potential issues for us to think about when considering a change in brand for a particular medicine.

Pharmac's [Tender Clinical Advisory Committee](#) gives us advice on every tender decision we make. The committee is made up of healthcare professionals, including doctors, nurse practitioners, and pharmacists. As needed, we also seek more advice from specialists in particular fields, such as cancer or mental health.

The feedback and advice we get makes sure our decisions support New Zealanders to live longer, healthier lives.

[More about the annual tender.](#)

## Other benefits from the annual tender

The tender can result in savings for the medicines budget. We can use the savings to fund new medicines and make changes to the tendered medicines. For example:

- If the medicine is currently partially funded, it could become fully funded if the tender was awarded
- The medicine could be added to the all-at-once ('stat') dispensing list, which would mean that people could collect prescriptions all at once, rather than monthly.
- We might change or remove funding restrictions so more people can use it (for example, a Special Authority restriction, endorsement, or prescriber-type restriction). We might consult on this separately before making a decision.
- Some medicines or formulations may become funded for the first time through the tender

We are interested in your feedback on potential changes for the medicines we are tendering.

On the [Pharmaceutical Schedule](#) you can search for your medicine to see all dispensing and funding restrictions that apply.

[More about the Pharmaceutical Schedule](#)

## Additional Special Terms

We have included Additional Special Terms in the draft 2024/25 Invitation to Tender contract for intra-uterine devices [Non-hormonal] (IUDs). This clause would require that potential suppliers offer education, training, and support resources to safely use the supplier's IUD product. This could include a description of the inserter and IUD materials and insertion instructions.

Any feedback on these Additional Special Terms will help inform the final contract.

### ***Intra-uterine device (Non-hormonal)***

You shall provide the following information when submitting a Tender Bid for the Pharmaceutical intra-uterine device [Non-hormonal] (IUD Tender Item):

- the size of the IUD Tender Item, including length and width measurements as well as the diameter of the inserter;
- a description of the material the inserter is made of;
- the duration of the therapeutic effect of the IUD Tender Item; and
- the metals which are contained in the IUD Tender Item.

You shall provide the following Resources at no cost for the IUD Tender Item, for the provision of education, training and support to healthcare professionals in respect of the use of the IUD Tender Item.

For the purposes of this clause "Resources" shall include but not be limited to the:

- provision of training materials (DVDs, pamphlets, leaflets, brochures) to healthcare professionals;
- provision of an information sheet explaining the differences between the current brand of intra-uterine device and your IUD Tender Item; and
- provision of presentations and/or demonstrations on the use of your IUD Tender Item to patients and/or healthcare professionals.

## Explanation of terms, symbols, and abbreviations

Some of the terms, abbreviations and symbols used in the draft tender list are quite specific.

Terms / abbreviations used in the draft tender list:

Term / abbreviation	Explanation
Tab	Tablet
Cap	Capsule
Liq	Liquid
Inj	Injection
Suppos	Suppository
Grans	Granules
OP	Original pack to be dispensed

Symbols used in the draft tender list:

Symbol	Explanation
Underlined	Tender items where there is currently a principal supply contract are underlined. The price and subsidy for these items are fixed until 30 June 2025 unless otherwise stated in the comments column, therefore a listing of a new brand could only occur after that date.
C	To be tendered for Principal Supply Status (community medicines).
H	To be tendered for Principal Supply Status (hospital medicines).
PCT	Pharmaceuticals for which Health New Zealand   Te Whatu Ora hospitals may claim a subsidy through Section B of the Pharmaceutical Schedule.
+	Pharmac has been advised of the existence of a patent.
*	There is no fully funded product available for this tender item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP). The supplier of the successful tender bid would be required to hold additional stock.
#	A rebate currently exists. Rebates mean the price published in the Pharmaceutical Schedule is higher than the actual net price paid. Accepting a rebate arrangement with a supplier means that we can fund a medicine at an affordable cost.

## Key dates

**30 July 2025** – Consultation begins

**10 September 2025** – Consultation closes

**September 2025** – Tender Clinical Advisory Committee meets

**Late October/Early November 2025** – Final Invitation to Tender issued

**December 2025** – Invitation to Tender closes

**January 2026** – Earliest tender results announced

**April 2026** – Earliest listing of new brands

## Providing feedback

Feedback should be provided to the Tender Analysts through our [online form](#) or by emailing [tenderconsult@pharmac.govt.nz](mailto:tenderconsult@pharmac.govt.nz).

Pharmac's Board (or its delegate) will consider all feedback you send by the closing date (4 pm on Monday 10 September 2025) before we finalise the 2025/26 Invitation to Tender.

## Your feedback may be shared

When you give feedback on a consultation, your feedback becomes official information that Pharmac holds. Pharmac has legal responsibilities for how we manage this official information, under laws such as the Official Information Act and Privacy Act.

Pharmac may receive a request from people for official information, which could include your feedback. Legally, Pharmac must consider whether your feedback should be released. Tell us if there is anything about your feedback that you would prefer wasn't released and we will take that into consideration

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
<b>Alfacalcidol</b>					
Cap 0.25 mcg	234,037	\$61,599	\$0.2632	C H 5%	
Cap 1 mcg	54,271	\$47,748	\$0.8798	C H 5%	
Oral drops 2 mcg per ml	14,540	\$44,114	\$3.0340	C H 5%	
<b>Calcium carbonate</b>					
Tab	8,991,144	\$261,822	\$0.0291	C H 5%	Preference for tab 1.25 g - 1.5 g.
<b>Colecalciferol</b>					
Cap/Tab 1.25 mg	4,692,968	\$1,427,460	\$0.3042	C H 5%	Preference for a tablet.
<b>Docusate Sodium</b>					
Tab 50 mg	995,163	\$31,845	\$0.0320	C H 5%	
Tab 120 mg	1,623,423	\$80,846	\$0.0498	C H 5%	
<b>Famotidine</b>					
Inj 10 mg per ml, 2 ml				H 5%	
Inj 10 mg per ml, 4 ml	15,022	\$85,655	\$5.7020	C H 5%	Note this is currently listed as a Cost Brand Source (CBS).
<b>Fibre supplement</b>					
Powder/granules	104,149,000	\$4,165,960	\$0.0400	C H 5%	Units and subsidy shown as per the ispaghula (psyllium) husk 500 g currently listed and expressed as 'per g'. Preference for a product containing psyllium husk.
<b>Glibenclamide</b>					
Tab 5 mg	194,701	\$14,603	\$0.0750	C H 5%	
<b>Gliclazide</b>					
Tab 80 mg	17,052,845	\$685,524	\$0.0402	C H 5%	
<b>Hyoscine N-butylbromide</b>					
Inj 20 mg. 1 ml	180,940	\$69,119	\$0.3820	@ C H 5%	
<b>Iodine supplement</b>					
Tab 150 mcg elemental	13,909,587	\$925,822	\$0.0666	C H 5%	Units and subsidy shown are for the currently listed potassium iodate.
<b>Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride</b>					
Powder for oral soln 13.125 g with potassium chloride 46.6 mg.sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	13,649,213	\$3,867,231	\$0.2833	C H 5%	
<b>Macrogol 3350 with sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid</b>					
Powder for oral soln				H 5%	
<b>Magnesium sulphate</b>					
Inj 2 mmol per ml, 5ml	23,838	\$89,464	\$3.7530	@ C H 5%	
<b>Mebeverine hydrochloride</b>					
Tab 135 mg	2,970,190	\$280,505	\$0.0944	C H 5%	
<b>Multivitamins</b>					
Tab (BPC cap strength)	18,137,430	\$335,542	\$0.0185	C H 5%	
<b>Nystatin</b>					
Oral liq 100,000 u per ml	1,740,792	\$161,023	\$0.0925	C H 5%	
<b>Omeprazole</b>					
Inf 40 mg				H 5%	Currently listed in the hospital on the Pharmaceutical Schedule as Inj 40 mg. Aggregated tender bids cannot be made across inf, inj and caps.
Inj 40 mg	7,942	\$59,374	\$7.4760	C H 5%	Currently listed on the Pharmaceutical Schedule as Inj 40 mg ampoule with diluent. Aggregated tender bids cannot be made across inf, inj and caps.
Cap 10 mg	8,797,755	\$201,381	\$0.0229	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack. Aggregated tender bids cannot be made across inf, inj and caps.
<b>Principal Supply Status</b>					
#=rebate *=part charge @=ASP +=patent					



SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Omeprazole</b>					
<u>Cap 20 mg</u>	120,039,820	\$2,693,694	\$0.0224	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack. Aggregated tender bids cannot be made across inf, inj and caps.
<u>Cap 40 mg</u>	35,514,336	\$1,254,721	\$0.0353	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack. Aggregated tender bids cannot be made across inf, inj and caps.
<b>Pancreatic enzyme</b>					
Cap 150 mg	2,790,918	\$974,868	\$0.3493	C H 5%	Pharmac would consider bids which contain the ranges of 9,000 -11,000BP u lipase, 8,000-10,000 BP u amylase and 150-600 BP u protease.
Cap 175 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider bids which contain the ranges of 20,000-25,000 BP u lipase, 22,500 BP u amylase and 1250 BP u protease.
Cap 300 mg	8,114,966	\$7,658,905	\$0.9438	C H 5%	Pharmac would consider bids which contain the range of 24,000-25,000 BP u lipase, 18,000 BP u amylase and 1,000-1,500 BP u protease.
Cap 420 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider bids which contain the range of 25,000-26,000 BP u lipase, 35,000 BP u amylase and 1,000-1,600 BP u protease.
<b>Poloxamer</b>					
<u>Oral drops 10%</u>	268,380	\$37,305	\$0.1390	C H 5%	
<b>Pyridoxine hydrochloride</b>					
<u>Tab 25 mg</u>	1,690,070	\$64,409	\$0.0381	C H 5%	
<b>Triamcinolone acetonide</b>					
<u>0.1% in Dental Paste USP</u>	148,375	\$162,916	\$1.0980	C H 5%	Aggregated tender bids cannot be made across dental paste, crm, inj and oint.
<b>Ursodeoxycholic acid</b>					
<u>Cap 250 mg - 300 mg</u>	1,429,727	\$485,392	\$0.3395	C H 5%	Units and subsidy shown are for the currently listed cap 200 mg.

Blood and Blood Forming Organs

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Aspirin</b>					
<u>Tab 100 mg</u>	87,001,576	\$1,111,880	\$0.0128	C H 5%	
<b>Glucose [Dextrose]</b>					
<u>Inj 50%, 10 ml - 20 ml</u>	12,219	\$84,922	\$6.9500	C H 5%	Inj 50%, 10 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 10 ml ampoule.
<u>Inj 50%, 90 ml - 100 ml</u>	386	\$6,755	\$17.5000	C H 5%	Inj 50%, 90 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 90 ml ampoule.
<b>Prasugrel</b>					
Tab 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply. Preference for a tablet containing a scoreline.
Tab 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
<b>Water for injection</b>					
Purified for inj, 250 ml bag				H 5%	

Principal Supply Status

#=rebate \*=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
ACE Inhibitor					
<u>Oral liquid</u>	73,900	\$63,554	\$0.8600	C H 5%	Units and subsidy shown are for the currently listed captopril oral liq.
Ambrisentan					
<u>Tab 5 mg</u>	7,321	\$48,807	\$6.6667	C H 5%	
<u>Tab 10 mg</u>	22,072	\$147,147	\$6.6667	C H 5%	
Amloride hydrochloride with furosemide					
<u>Tab 5 mg with furosemide 40 mg</u>	110,718	\$34,124	\$0.3082	C H 5%	
Amlodipine					
<u>Tab 2.5 mg</u>	19,359,977	\$311,889	\$0.0161	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 5 mg</u>	35,089,318	\$471,600	\$0.0134	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 10 mg</u>	18,412,763	\$268,090	\$0.0146	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Bendroflumethiazide [Bendrofluazide]					
<u>Tab 2.5 mg</u>	15,641,629	\$1,611,088	\$0.1030	C H 5%	
<u>Tab 5 mg</u>	2,532,266	\$308,936	\$0.1220	C H 5%	
Bisoprolol fumarate					
<u>Tab 2.5 mg</u>	20,387,770	\$308,059	\$0.0151	C H 5%	Preference for a scored tablet, and for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 5 mg</u>	10,089,837	\$214,106	\$0.0212	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 10 mg</u>	3,198,174	\$96,297	\$0.0301	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Clonidine					
<u>TDDS 2.5 mg, 100 mcg per day</u>	86,831	\$253,981	\$2.9250 @	C H 5%	
<u>TDDS 5 mg, 200 mcg per day</u>	31,644	\$101,261	\$3.2000 @	C H 5%	
<u>TDDS 7.5 mg, 300 mcg per day</u>	25,654	\$114,802	\$4.4750 @	C H 5%	
Colestyramine					
<u>Powder for oral liq 4 g</u>	659,971	\$811,764	\$1.2300	C H 5%	
Ephedrine					
<u>Inj 3 mg per ml, 10 ml prefilled syringe</u>				H 5%	
<u>Inj 30 mg per ml, 1ml</u>				H 5%	
Ezetimibe					
<u>Tab 10 mg</u>	12,408,222	\$727,990	\$0.0587	C H 5%	
Furosemide [Frusemide]					
<u>Tab 20 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.
Indapamide					
<u>Tab 2.5 mg</u>	2,157,711	\$383,598	\$0.1778	C H 5%	
Isosorbide mononitrate					
<u>Tab 20 mg</u>	680,162	\$152,968	\$0.2249	C H 5%	
<u>Tab long-acting 40 mg</u>	769,986	\$251,531	\$0.3267	C H 5%	
<u>Tab long-acting 60 mg</u>	6,252,824	\$937,924	\$0.1500	C H 5%	
Ivabradine					
<u>Tab 5 mg</u>				H 5%	
Labetalol					
<u>Tab 100 mg</u>	1,130,502	\$163,923	\$0.1450	C H 5%	
<u>Tab 200 mg</u>	724,296	\$195,560	\$0.2700	C H 5%	
Losartan					
<u>Tab 12.5 mg</u>	5,895,998	\$140,384	\$0.0238	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
<b>Losartan</b>					
Tab 25 mg	13,689,621	\$373,179	\$0.0273	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 50 mg	24,989,840	\$850,904	\$0.0341	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 100 mg	13,690,476	\$744,762	\$0.0544	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<b>Metaraminol Tartrate</b>					
Inj 10 mg per ml, 1 ml			@	H 5%	
<b>Metoprolol succinate</b>					
Tab long-acting Very Low Dose (20-25 mg)	23,246,889	\$1,084,932	\$0.0467	C H 5%	Units and subsidy shown are for the currently listed tab 23.75 mg.
Tab long-acting Low Dose (40-50 mg)	32,686,631	\$1,325,770	\$0.0406	C H 5%	Units and subsidy shown are for the currently listed tab 47.5 mg.
Tab long-acting Medium Dose (90-100 mg)	19,815,103	\$1,153,635	\$0.0582	C H 5%	Units and subsidy shown are for the currently listed tab 95 mg.
Tab long-acting High Dose (180-200 mg)	3,572,018	\$387,350	\$0.1084	C H 5%	Units and subsidy shown are for the currently listed tab 190 mg.
<b>Nifedipine</b>					
Tab long-acting 10 mg	494,796	\$171,590	\$0.3468	C H 5%	
Tab long-acting 20 mg	801,348	\$141,999	\$0.1772	C H 5%	
Tab long-acting 30 mg	692,453	\$236,424	\$0.3414	C H 5%	
Tab long-acting 60 mg	128,852	\$68,047	\$0.5281	C H 5%	
<b>Perindopril with amlodipine</b>					
Tab 10 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding perindopril with amlodipine if cost saving or cost neutral to current combined cost of funded ACE inhibitor and calcium channel blocker.
Tab 10 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding perindopril with amlodipine if cost saving or cost neutral to current combined cost of funded ACE inhibitor and calcium channel blocker.
Tab 5 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding perindopril with amlodipine if cost saving or cost neutral to current combined cost of funded ACE inhibitor and calcium channel blocker.
Tab 5 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding perindopril with amlodipine if cost saving or cost neutral to current combined cost of funded ACE inhibitor and calcium channel blocker.
<b>Pravastatin</b>					
Tab 20 mg	3,357,836	\$240,421	\$0.0716	C H 5%	
Tab 40 mg	1,977,605	\$242,257	\$0.1225	C H 5%	
<b>Prazosin Hydrochloride</b>					
Tab 1 mg	52,758	\$2,918	\$0.0553	C H 5%	
Tab 2 mg	34,352	\$2,405	\$0.0700	C H 5%	
Tab 5 mg	10,298	\$1,205	\$0.1170	C H 5%	
<b>Propranolol</b>					
Oral liq 4 mg per ml	273,477			C H 0%	Note this is currently listed as a Cost Brand Source (CBS). Units are expressed as 'per ml'

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Rosuvastatin (current access)					
<u>Tab 10 mg</u>	4,284,988	\$241,373	\$0.0563	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
<u>Tab 20 mg</u>	5,682,965	\$513,342	\$0.0903	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
<u>Tab 40 mg</u>	5,741,616	\$870,831	\$0.1517	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
<u>Tab 5 mg</u>	2,138,516	\$91,956	\$0.0430	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
Rosuvastatin (widened access)					
Tab 10 mg				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Tab 20 mg				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Tab 40 mg				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Tab 5 mg				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Simvastatin					
<u>Tab 10 mg</u>	2,270,930	\$42,398	\$0.0187	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 20 mg</u>	9,254,200	\$261,154	\$0.0282	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 40 mg</u>	7,972,428	\$364,101	\$0.0457	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 80 mg</u>	558,746	\$54,696	\$0.0979	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Telmisartan					
Tab 40 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan if cost saving or cost neutral to a current angiotensin II antagonist.
Tab 80 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan if cost saving or cost neutral to a current angiotensin II antagonist.
Telmisartan with amlodipine					
Tab 40 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan with amlodipine if cost saving or cost neutral to current combined cost of funded angiotensin II antagonist and calcium channel blocker.
Tab 40 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan with amlodipine if cost saving or cost neutral to current combined cost of funded angiotensin II antagonist and calcium channel blocker.
Tab 80 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan with amlodipine if cost saving or cost neutral to current combined cost of funded angiotensin II antagonist and calcium channel blocker.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
<b>Telmisartan with amlodipine</b>					
Tab 80 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan with amlodipine if cost saving or cost neutral to current combined cost of funded angiotensin II antagonist and calcium channel blocker.

Dermatologicals

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
<b>Acitretin</b>					
Cap 10 mg	583,616	\$254,848	\$0.4367	C H 5%	Preference for a blister pack.
Cap 25 mg	104,120	\$99,556	\$0.9562	C H 5%	Preference for a blister pack.
<b>Adapalene (current access)</b>					
Crm 0.1%				C H 5%	Same restriction as adapalene gel 0.1% would apply. Not currently listed in the community on the Pharmaceutical Schedule. Pharmac would only award a tender for current or widened access.
Gel 0.1%	1,007,370	\$768,623	\$0.7630#	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
<b>Adapalene (widened access)</b>					
Crm 0.1%				C H 5%	Restrictions would not apply. Not currently listed in the community on the Pharmaceutical Schedule. Pharmac would only award a tender for current or widened access.
Gel 0.1%				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
<b>Amorolfine</b>					
Nail soln 5%	291,905	\$1,276,792	\$4.3740	C H 5%	
<b>Benzyl benzoate (funded with restriction)</b>					
10% - 25%				C H 5%	Restricted to scabies hyper-infestation or for second line treatment where topical therapy has failed. Not currently listed on the Schedule. Pharmac would only award a tender for benzyl benzoate funded with restriction or funded without restriction.
<b>Benzyl benzoate (funded without restriction)</b>					
10% - 25%				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would only award a tender for benzyl benzoate funded with restriction or funded without restriction.
<b>Betamethasone Dipropionate</b>					
Crm 0.05% (pack size greater than 30 g)	639,530	\$460,462	\$0.7200	C H 5%	
Oint 0.05% (pack size greater than 30 g)	420,760	\$302,947	\$0.7200	C H 5%	
<b>Ciclopirox olamine</b>					
Nail lacquer 8%				C H 5%	Not current listed in the community on the Pharmaceutical Schedule. Special Authority restrictions may apply.
<b>Dimethicone</b>					
Crm 10%	4,091,240	\$40,201	\$0.0098	C H 5%	Preference for a pump bottle.
<b>Econazole nitrate</b>					
Foaming soln 1%, 10 ml sachets	42,828	\$141,190	\$3.2967 *	C H 5%	Awarding this Tender item would result in removal of the part charge.
<b>Emulsifying ointment</b>					
Oint BP (pack size of 200 g or less)				H 5%	Preference for an SLS-free product
Oint BP (pack size greater than 200 g)	42,092,892	\$263,502	\$0.0063	C H 5%	Preference for an SLS-free product
Principal Supply Status				#=rebate *=part charge @=ASP +=patent	

## SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

### Dermatologicals

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Hydrocortisone with paraffin liquid and lanolin</b>					
<u>Lotn 1% with paraffin liquid and lanolin (pack size 50 - 250 ml)</u>	13,488,782	\$692,244	\$0.0513	C H 5%	
<b>Ketoconazole</b>					
<u>Shampoo 2%</u>	9,091,600	\$371,846	\$0.0409	C H 5%	
<b>Malathion (funded with restriction)</b>					
0.5%				C H 5%	Restricted to scabies hyper-infestation or for second line treatment where topical therapy has failed. Not currently listed on the Schedule. Pharmac would only award a tender for malathion funded with restriction or funded without restriction.
<b>Malathion (funded without restriction)</b>					
0.5%				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would only award a tender for malathion funded with restriction or funded without restriction.
<b>Methylprednisolone aceponate</b>					
<u>Crm 0.1%</u>	538,065	\$177,561	\$0.3300	C H 5%	
<u>Oint 0.1%</u>	299,685	\$98,896	\$0.3300	C H 5%	
<b>Miconazole nitrate</b>					
<u>Crm 2% (15 g - 20 g pack)</u>	3,524,745	\$211,485	\$0.0600	C H 5%	A 15 g pack is currently listed on the Pharmaceutical Schedule.
<b>Paraffin</b>					
<u>White soft (pack size 2000 g or more)</u>	1,979,122	\$15,041	\$0.0076	C 5%	Only funded in combination.
<u>White soft (pack size 500 g or less)</u>	128,146	\$1,350	\$0.0105	C H 5%	
<b>Permethrin (combined market)</b>					
Crm 5%				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac reserves the right to award a single tender for the whole permethrin market or two separate tenders for cream and lotion.
<u>Lotn 5%</u>	6,266,160	\$893,993	\$0.1427	C H 5%	Pharmac reserves the right to award a single tender for the whole permethrin market or two separate tenders for cream and lotion.
<b>Permethrin (split market)</b>					
Crm 5%				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac reserves the right to award a single tender for the entire permethrin market or two separate tenders for cream and lotion.
<u>Lotn 5%</u>	6,266,160	\$893,993	\$0.1427	C H 5%	Pharmac reserves the right to award a single tender for the entire permethrin market or two separate tenders for cream and lotion.
<b>Pimecrolimus</b>					
<u>Crm 1%</u>	183,285	\$403,227	\$2.2000	C H 5%	Restrictions may apply.
<b>Pine tar with triethanolamine lauryl sulphate and fluorescein</b>					
<u>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</u>	23,272,107	\$251,804	\$0.0108	C H 5%	
<b>Sulfadiazine silver</b>					
1%	343,450	\$74,185	\$0.2160	C H 5%	Current restrictions apply. Pharmac would award a tender for any topical formulation.
<b>Tacrolimus</b>					
<u>Oint 0.1%</u>	304,560	\$335,016	\$1.1000	C H 5%	Restrictions may apply.
<b>Triamcinolone acetonide</b>					
<u>Crm 0.02%</u>	6,142,600	\$398,655	\$0.0649	C H 5%	Aggregated tender bids cannot be made across dental paste, crm, inj and oint.

Principal Supply Status

#=rebate \*=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals						
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments	
Line Item						
Triamcinolone acetonide						
<u>Oint 0.02%</u>	3,457,400	\$226,114	\$0.0654	C H 5%	Aggregated tender bids cannot be made across dental paste, crm, inj and oint.	

Genito-Urinary System						
Chemical Name						
Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments
Cyproterone acetate with ethinyloestradiol						
<u>Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets</u>	7,982,100	\$241,379	\$0.0302	C H	5%	
Finasteride						
<u>Tab 5 mg</u>	7,672,069	\$367,492	\$0.0479	C H	5%	Preference for a blister pack.
Intra-uterine device (Non-hormonal)						
IUD Long	2,185	\$72,105	\$33.0000	C H	5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MDR certification. Special terms apply see Schedule 5.
IUD Medium	4,240	\$113,632	\$26.8000	C H	5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MDR certification. Special terms apply see Schedule 5.
IUD Short	4,204	\$125,279	\$29.8000	C H	5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MDR certification. Special terms apply see Schedule 5.
Nystatin						
<u>Vaginal crm 100,000 u per 5 g with applicator(s)</u>	166,725	\$12,671	\$0.0760	C H	5%	Units and subsidy expressed as 'per g'.
Oestriol						
<u>Crm 1 mg per g with applicator(s)</u>	5,784,870	\$2,680,304	\$0.4633	C H	5%	Applicator(s) should be multiple use and a measured dose.
<u>Pessaries 500 mcg</u>	602,361	\$303,186	\$0.5033	C H	5%	
Urinary alkaliniser						
<u>Effervescent</u>	2,135,481	\$266,935	\$0.1250	C H	5%	Units and subsidy shown are for the currently listed sodium citro-tartrate grans

Hormone Preparations - Systemic Excluding Contraceptive Hormones						
Chemical Name			Unit			
Line Item	Units	Cost	Subsidy		ABA Limit	Comments
Cabergoline						
Tab 0.5 mg (2 pack)	100,678	\$225,769	\$2.2425	C H	5%	Current Special Authority restrictions would apply. Units and cost shown are for the whole tab 0.5 mg market.
Tab 0.5 mg (8 pack)	100,678	\$225,769	\$2.2425	C H	5%	
Desmopressin acetate						
<u>Nasal spray 10 mcg per dose</u>	794,754	\$462,944	\$0.5825	C H	5%	
Oestriol						
<u>Tab 1 mg - 2 mg</u>	172,547	\$44,288	\$0.2567	C H	5%	Units and subsidy shown are for the currently listed tab 2 mg. Preference for 2 mg tablets to be scored.
Propylthiouracil						
Tab 50 mg	281,864	\$98,652	\$0.3500	C H	5%	



SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Triamcinolone acetonide					
<u>Inj 10 mg per ml, 1 ml</u>	5,767	\$24,706	\$4.2840	C H 10%	Preference for a preservative free product. Where a preservative free product is not awarded Pharmac reserves the right to list a preservative free product in addition to this product. Aggregated bids cannot be made across dental paste, crm, inj and oint.
<u>Inj 40 mg per ml, 1 ml</u>	80,097	\$843,101	\$10.5260	C H 5%	Preference for a preservative free product. Where a preservative free product is not awarded Pharmac reserves the right to list a preservative free product in addition to this product. Aggregated bids cannot be made across dental paste, crm, inj and oint.

Infections					
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Amoxicillin					
<u>Grans for oral liq 125 mg per 5 ml</u>	3,821,769	\$84,843	\$0.0222 @	C H 5%	Preference for a product which includes a measuring device and has a shelf life of at least 10 days after reconstitution.
<u>Grans for oral liq 250 mg per 5 ml</u>	54,422,863	\$1,529,282	\$0.0281 @	C H 5%	Preference for a product which includes a measuring device and has a shelf life of at least 10 days after reconstitution.
Amoxicillin clavulanate					
<u>Tab 500 mg with potassium clavulanate 125 mg</u>	11,240,505	\$1,787,240	\$0.1590 @	C H 5%	
Benzylpenicillin sodium [Penicillin G]					
<u>Inj 600 mg</u>	7,335	\$12,103	\$1.6500 @	C H 5%	
Cefazolin sodium					
<u>Inj 500 mg</u>	276	\$187	\$0.6780	C H 5%	
<u>Inj 1 g</u>	17,881	\$12,839	\$0.7180	C H 5%	
<u>Inj 2 g</u>	1,094	\$1,551	\$1.4180	C H 5%	
Cefotaxime					
<u>Inj 500 mg</u>				H 5%	
<u>Inj 1 g</u>				H 5%	
Ceftazidime					
<u>Inj 1 g</u>				H 5%	
Cefuroxime sodium					
<u>Inj 250 mg</u>				H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
<u>Inj 750 mg</u>				H 5%	
<u>Inj 1.5 g</u>				H 5%	
Chloramphenicol					
<u>Inj 1 g</u>				H 5%	Current restrictions may apply.
Ciprofloxacin					
<u>Tab 250 mg</u>	95,601	\$6,658	\$0.0696	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 500 mg</u>	658,181	\$72,867	\$0.1107	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 750 mg</u>	21,795	\$3,736	\$0.1714	C H 5%	Preference for a scored, dispersible tablet.
Clarithromycin					
<u>Inj 500 mg</u>				H 5%	
Colistin sulphomethate					
<u>Inj 1,000,000 - 4,500,000 iu</u>	420	\$9,100	\$21.6670	C H 5%	
Darunavir					
<u>Tab 400 mg</u>	90,476	\$226,190	\$2.5000	C H 5%	Preference for a dispersible tablet.
<u>Principal Supply Status</u>					
#=rebate *=part charge @=ASP +=patent					



SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections							
Chemical Name							
Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments	
Darunavir							
Tab 600 mg	25,670	\$96,263	\$3.7500		C H 5%	Preference for a dispersible tablet.	
Entecavir							
Tab 0.5 mg	1,666,587	\$668,851	\$0.4013		C H 5%		
Ertapenem							
Inj 1 g					H 5%		
Flucloxacillin sodium							
Inj 250 mg	90	\$383	\$4.2600		C H 5%		
Inj 500 mg	608	\$2,774	\$4.5630		C H 5%		
Inj 1 g	4,569	\$5,483	\$1.2000		C H 5%		
Fluconazole							
Cap 50 mg	265,383	\$38,860	\$0.1464		C H 5%		
Cap 150 mg	160,992	\$72,446	\$0.4500		C H 5%		
Cap 200 mg	83,518	\$26,547	\$0.3179		C H 5%		
Lamivudine							
Tab 100 mg	55,929	\$24,089	\$0.4307		C H 5%		
Tab 150 mg	47,749	\$77,990	\$1.6333		C H 5%		
Meropenem							
Inj 500 mg					H 5%		
Inj 1 g				@	H 5%		
Metronidazole							
Tab 200 mg	301,749	\$31,213	\$0.1034		C H 5%	Preference for a scored, dispersible tablet.	
Tab 400 mg	2,185,844	\$446,546	\$0.2043		C H 5%		
Inj 5 mg per ml, 100 ml				@	H 5%	Preference for a bag presentation with space to add another antibiotic.	
Minocycline hydrochloride							
Inj 100 - 200 mg					H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.	
Moxifloxacin							
Inj 400 mg					H 5%		
Tab 400 mg	20,582	\$172,885	\$8.4000		C H 5%		
Nitrofurantoin							
Cap modified-release 100 mg	2,119,477	\$1,721,015	\$0.8120		C H 5%		
Pentamidine							
Inj 300 mg					H 5%		
Rifampicin							
Cap 150 mg	70,091	\$41,031	\$0.5854	@	C H 5%	Aggregated tender bids cannot be made across caps, inj and oral liq.	
Cap 300 mg	226,819	\$276,855	\$1.2206	@	C H 5%	Aggregated tender bids cannot be made across caps, inj and oral liq.	
Inj 600 mg					H 5%	Aggregated tender bids cannot be made across caps, inj and oral liq.	
Oral liq 100 mg per 5 ml	73,691	\$15,475	\$0.2100	@	C H 5%	Aggregated tender bids cannot be made across caps, inj and oral liq.	
Rifampicin with isoniazid and ethambutol and pyrazinamide							
150 mg with isoniazid 75 mg and ethambutol 275 mg and pyrazinamide 400 mg					C H 5%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Pharmac would award a tender for any oral formulation of this combination.	
Rifampicin with isoniazid and pyrazinamide							
150 mg with isoniazid 75 mg and pyrazinamide 400 mg					C H 5%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Pharmac would award a tender for any oral formulation of this combination.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections							
Chemical Name	Units	Cost	Unit Subsidy		ABA Limit	Comments	
Line Item							
Roxithromycin							
Tab 150 mg	1,388,218	\$366,212	\$0.2638	@	C H	5%	
Tab 300 mg	746,508	\$373,254	\$0.5000	@	C H	5%	
Terbinafine							
Tab 250 mg	2,468,564	\$263,618	\$0.1068		C H	5%	
Tobramycin							
Solution for inhalation 60 mg per ml, 5 ml	4,788	\$33,772	\$7.0536		C H	5%	Preference for a product that is sodium bisulfite free and/or preservative free and/or suitable for use via nebuliser.
Vancomycin hydrochloride							
Inj 500 mg	8,218	\$27,777	\$3.3800	@	C H	5%	
Vancomycin hydrochloride (current access)							
Cap 125 mg					C H	5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply. Pharmac would only award a tender for current or widened access.
Cap 250 mg					C H	5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply. Pharmac would only award a tender for current or widened access.
Vancomycin hydrochloride (widened access)							
Cap 125 mg					C H	5%	For treatment of Clostridium difficile in line with 2025 Australasian Society of Infectious Diseases guidelines. Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Pharmac would only award a tender for current or widened access.
Cap 250 mg					C H	5%	For treatment of Clostridium difficile in line with 2025 Australasian Society of Infectious Diseases guidelines. Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Pharmac would only award a tender for current or widened access.
Voriconazole							
Powder for oral suspension 40 mg per ml	8,120	\$176,694	\$21.7603		C H	5%	
Musculoskeletal System							
Chemical Name	Units	Cost	Unit Subsidy		ABA Limit	Comments	
Line Item							
Allopurinol							
Tab 100 mg	32,681,609	\$587,942	\$0.0180		C H	5%	Preference for a scored tablet.
Tab 300 mg	24,038,383	\$1,081,727	\$0.0450		C H	5%	Preference for a scored tablet.
Atracurium besylate							
Inj 10 mg per ml, 2.5 ml				@	H	5%	
Febuxostat							
Tab 80 mg	806,366	\$136,219	\$0.1689		C H	5%	Current restrictions may apply.
Tab 120 mg	192,534	\$81,001	\$0.4207		C H	5%	Current restrictions may apply.
Ibuprofen							
Tab 200 mg - blister pack (pack size greater than or equal to 100 and less than or equal to 1,000)	56,733,456	\$1,214,096	\$0.0214	@	C H	5%	
Tab 200 mg - blister pack (pack size less than or equal to 20)				@	H	5%	Not currently listed on the Pharmaceutical Schedule.
Suxamethonium chloride							
Inj 50 mg per ml, 2 ml				@	H	5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System						
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments	
Line Item						
Alfentanil						
Inj 0.5 mg per ml, 2 ml ampoule			@	H	5%	
Amitriptyline						
Tab 10 mg	27,073,774	\$809,506	\$0.0299	C H	5%	Preference for a scored and/or dispersible tablet.
Tab 25 mg	7,973,464	\$158,672	\$0.0199	C H	5%	
Tab 50 mg	3,337,898	\$104,810	\$0.0314	C H	5%	
Aripiprazole						
Tab 5 mg	1,210,474	\$423,666	\$0.3500	C H	5%	
Tab 10 mg	894,076	\$312,927	\$0.3500	C H	5%	
Tab 15 mg	325,364	\$113,877	\$0.3500	C H	5%	
Tab 20 mg	214,122	\$74,943	\$0.3500	C H	5%	
Tab 30 mg	98,915	\$34,620	\$0.3500	C H	5%	
Aspirin						
Tab dispersible or soluble 300 mg	622,871	\$35,192	\$0.0565	C H	5%	
Atomoxetine						
Cap 10 mg	365,900	\$562,180	\$1.5364	C H	5%	
Cap 18 mg	128,417	\$208,999	\$1.6275	C H	5%	
Cap 25 mg	327,944	\$518,853	\$1.5821	C H	5%	
Cap 40 mg	489,565	\$807,958	\$1.6504	C H	5%	
Cap 60 mg	115,832	\$212,262	\$1.8325	C H	5%	
Cap 80 mg	92,594	\$215,612	\$2.3286	C H	5%	
Cap 100 mg	47,699	\$111,940	\$2.3468	C H	5%	
Betahistine dihydrochloride						
Tab 16 mg	5,130,849	\$189,841	\$0.0370	C H	5%	
Bupivacaine hydrochloride						
Inj 2.5 mg per ml, 20 ml ampoule sterile pack				H	5%	Product needs to be sterile.
Inj 5 mg per ml, 4 ml				H	5%	
Dexmedetomidine hydrochloride						
Inj 100 mcg per ml, 2 ml vial			@	H	5%	
Diazepam						
Tab 2 mg	2,825,363	\$536,819	\$0.1900	C H	5%	Preference for a scored tablet.
Tab 5 mg	3,984,227	\$916,372	\$0.2300	C H	5%	
Disulfiram						
Tab 200 mg	429,666	\$1,015,729	\$2.3640	C H	5%	
Donepezil hydrochloride						
Tab 5 mg	1,826,587	\$80,461	\$0.0441	C H	5%	
Tab 10 mg	1,467,717	\$96,106	\$0.0655	C H	5%	
Duloxetine						
Cap 30 mg				C H	5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Cap 60 mg				C H	5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Escitalopram						
Tab 10 mg	18,102,687	\$510,677	\$0.0282	C H	5%	Preference for a scored tablet.
Tab 20 mg	6,586,917	\$350,490	\$0.0532	C H	5%	
Fentanyl						
Inj 10 mcg per ml, 100 ml premixed bag			@	H	5%	
Granisetron						
Inj 1 mg per ml				H	5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System						
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments	
Line Item						
Hyoscine hydrobromide						
Patch 1 mg per 72 hours	51,097	\$452,208	\$8.8500	C H	5%	
Lithium carbonate						
Immediate-release tab/cap	2,847,436	\$1,018,813	\$0.3578	C H	5%	Units and subsidy shown are for the currently listed cap 250 mg.
Metoclopramide hydrochloride						
Tab 10 mg	6,364,406	\$99,921	\$0.0157	C H	5%	
Morphine						
Oral liq 1 mg per ml	8,160,815	\$775,277	\$0.0950	C H	5%	Preference for a product with child-resistant packaging. Preference for an excipient free product. Aggregated tender bids cannot be made across inj and oral liq.
Oral liq 10 mg per ml	43,045	\$8,663	\$0.2013	C H	5%	Preference for a product with child-resistant packaging. Preference for an excipient free product. Aggregated tender bids cannot be made across inj and oral liq.
Oral liq 2 mg per ml	258,501	\$30,438	\$0.1178	C H	5%	Preference for a product with child-resistant packaging. Preference for an excipient free product. Aggregated tender bids cannot be made across inj and oral liq.
Oral liq 5 mg per ml	279,022	\$39,342	\$0.1410	C H	5%	Preference for a product with child-resistant packaging. Preference for an excipient free product. Aggregated tender bids cannot be made across inj and oral liq.
Inj 1 mg per ml, 10 ml syringe				H	5%	Aggregated tender bids cannot be made across inj and oral liq.
Inj 1 mg per ml, 50 ml syringe				H	5%	Aggregated tender bids cannot be made across inj and oral liq.
Inj 1 mg per ml, 100 ml bag				H	5%	Aggregated tender bids cannot be made across inj and oral liq.
Naltrexone hydrochloride						
Tab 50 mg	334,673	\$929,611	\$2.7777	C H	5%	
Nortriptyline hydrochloride						
Tab 10 mg	17,865,779	\$439,498	\$0.0246	C H	5%	
Tab 25 mg	10,052,149	\$351,222	\$0.0349	C H	5%	
Olanzapine						
Orodispersible tab 5 mg	541,016	\$46,760	\$0.0864	C H	5%	Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Orodispersible tab 10 mg	707,263	\$72,997	\$0.1032	C H	5%	Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Tab 2.5 mg	2,405,742	\$112,276	\$0.0467	C H	5%	Preference for a pack size of 30 or 90 tablets in a bottle pack. Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Tab 5 mg	3,057,714	\$196,703	\$0.0643	C H	5%	Preference for a pack size of 30 or 90 tablets in a bottle pack. Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Tab 10 mg	3,336,239	\$214,620	\$0.0643	C H	5%	Preference for a pack size of 30 or 90 tablets in a bottle pack. Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Ondansetron						
Tab disp 4 mg	4,179,768	\$234,067	\$0.0560	C H	5%	
Tab disp 8 mg	1,467,673	\$132,091	\$0.0900	C H	5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System							
Chemical Name	Units	Cost	Unit Subsidy		ABA Limit	Comments	
Line Item							
Oxycodone hydrochloride							
Oral liq 1 mg per ml	576,572	\$85,517	\$0.1483		C H 5%	Preference for a pack size of 250 ml or less. Preference for a shelf life of at least 30 days after opening.	
Paracetamol							
<u>Tab 500 mg - blister pack (pack size greater than or equal to 100 and less than or equal to 1,000)</u>	403,413,550	\$7,967,418	\$0.0198	@	C H 5%		
Tab 500 mg - bottle pack (pack size greater than or equal to 1,000)	57,151,142	\$1,024,148	\$0.0179	@	C H 5%		
<u>Suppos 125 mg</u>	171,851	\$73,724	\$0.4290		C H 5%		
<u>Suppos 250 mg</u>	111,460	\$60,077	\$0.5390		C H 5%		
<u>Suppos 500 mg</u>	123,201	\$40,780	\$0.3310		C H 5%		
Prochlorperazine							
<u>Tab 5 mg</u>	3,941,959	\$394,196	\$0.1000		C H 5%		
Quetiapine							
<u>Tab 25 mg</u>	32,164,942	\$843,365	\$0.0262		C H 5%	Preference for a scored tablet. Preference for a pack size of 30 or 90 tablets in a blister pack.	
<u>Tab 100 mg</u>	4,338,131	\$308,484	\$0.0711		C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.	
<u>Tab 200 mg</u>	1,135,901	\$138,455	\$0.1219		C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.	
<u>Tab 300 mg</u>	492,015	\$86,541	\$0.1759		C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.	
Remifentanil hydrochloride							
<u>Inj 1 mg</u>				@	H 5%		
<u>Inj 2 mg</u>				@	H 5%		
Risperidone							
<u>Oral liq 1 mg per ml</u>	519,024	\$178,025	\$0.3430		C H 5%		
<u>Tab 0.5 mg</u>	4,170,789	\$150,857	\$0.0362		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
<u>Tab 1 mg</u>	2,184,218	\$88,832	\$0.0407		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
<u>Tab 2 mg</u>	1,037,473	\$47,029	\$0.0453		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
<u>Tab 3 mg</u>	425,578	\$31,918	\$0.0750		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
<u>Tab 4 mg</u>	206,452	\$21,506	\$0.1042		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
Rizatriptan							
<u>Tab orodispersible 10 mg</u>	2,862,426	\$461,795	\$0.1613		C H 5%		
Ropivacaine hydrochloride							
<u>Inj 2 mg per ml, 10 ml ampoule</u>					H 5%		
<u>Inj 2 mg per ml, 20 ml</u>					H 5%		
<u>Inj 2 mg per ml, 100 ml</u>					H 5%		
<u>Inj 2 mg per ml, 200 ml</u>					H 5%		
<u>Inj 7.5 mg per ml, 10 ml</u>					H 5%		
<u>Inj 7.5 mg per ml, 20 ml</u>					H 5%		
<u>Inj 10 mg per ml, 10 ml</u>					H 5%		
<u>Inj 10 mg per ml, 20 ml</u>					H 5%		
Temazepam							
<u>Tab 10 mg</u>	2,990,025	\$167,441	\$0.0560		C H 5%	Preference for a scored tablet.	
Tramadol hydrochloride							
Cap 50 mg	28,470,542	\$948,069	\$0.0333		C H 5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System						
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit    Comments		
Line Item						
Tramadol hydrochloride						
<u>Inj 50 mg per ml, 1 ml ampoule</u>				H    5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.	
<u>Inj 50 mg per ml, 2 ml ampoule</u>				H    5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.	
<u>Tab sustained-release 100 mg</u>	4,555,330	\$444,145	\$0.0975	C H    5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.	
<u>Tab sustained-release 150 mg</u>	375,910	\$55,447	\$0.1475	C H    5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.	
<u>Tab sustained-release 200 mg</u>	253,890	\$48,239	\$0.1900	C H    5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.	

Oncology Agents and Immunosuppressants							
Chemical Name		Units	Cost	Unit Subsidy	ABA Limit		Comments
Line	Item						
Anastrozole							
	<u>Tab 1 mg</u>	570,010	\$83,410	\$0.1463	C H	5%	
Bicalutamide							
	<u>Tab 50 mg</u>	728,880	\$108,814	\$0.1493	C H	5%	
Calcium folinate							
	Inj 350 mg				PCT	H	5%
	Inj 50 mg		\$370,938	\$22.4400	PCT	C H	5% Please note this line item is currently listed on the Pharmaceutical Schedule as inj 10 mg per ml, 5 ml vial.
	Inj 100 mg				PCT	H	5%
	Inj 300 mg				PCT	H	5%
	Inj 1 g				PCT	H	5%
Docetaxel							
	<u>Inj 80 mg</u>				PCT	H	5% Preference for products where stability data >48 hours post-compounding.
Exemestane							
	<u>Tab 25 mg</u>	582,154	\$191,337	\$0.3287	C H	5%	
Fludarabine phosphate							
	Tab 10 mg	1,779	\$36,647	\$20.6000	PCT	C H	5% Preference for blister packaging.
Gemcitabine hydrochloride							
	Inj 1 g				PCT	H	5% Not currently listed in the hospital on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Hydroxyurea							
	<u>Cap 500 mg</u>	1,509,348	\$312,737	\$0.2072	PCT	C H	5% Preference for a blister pack.
Imatinib mesilate							
	<u>Cap 100 mg</u>	182,740	\$136,841	\$0.7488	C H	5%	
	<u>Cap 400 mg</u>	144,158	\$335,215	\$2.3253	C H	5%	
Melphalan							
	<u>Inj 50 mg vial</u>				PCT	H	5%
Methotrexate							
	<u>Inj 100 mg per ml, 50 ml</u>				PCT	H	5% Preference for products where stability data >48 hours post-compounding.
	Inj 100 mg per ml, 10 ml vial			\$25.0000	PCT	C H	5%
Octreotide							
	Inj 50 mcg per ml, 1 ml	1,414	\$7,800	\$5.5160	C H	5%	
	Inj 100 mcg per ml, 1 ml	5,014	\$48,636	\$9.7000	C H	5%	

Principal Supply Status

#=rebate    \*=part charge    @=ASP    +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Oncology Agents and Immunosuppressants

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
<b>Octreotide</b>					
Inj 500 mcg per ml, 1 ml	1,901	\$43,001	\$22.6200	C H 5%	
<b>Paclitaxel</b>					
Inj 100 mg				PCT H 5%	Preference for products where stability data >48 hours post-compounding.
Inj 300 mg				PCT H 5%	Preference for products where stability data >48 hours post-compounding.
<b>Tamoxifen citrate</b>					
Tab 10 mg	58,702	\$14,676	\$0.2500	C H 5%	
Tab 20 mg	1,633,289	\$144,824	\$0.0887	C H 5%	
<b>Thiotepa</b>					
Inj 15 mg				PCT H 5%	
Inj 100 mg				PCT H 5%	

Respiratory System and Allergies

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
<b>Cetirizine hydrochloride</b>					
Tab 10 mg	65,284,775	\$1,116,370	\$0.0171	C H 5%	Preference for a pack size of 90 tablets.

Sensory Organs

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
<b>Atropine sulphate</b>					
Eye drops 1%	135,765	\$165,362	\$1.2180	C H 5%	
<b>Cyclopentolate hydrochloride</b>					
Eye drops 1%	31,710	\$53,188	\$1.6773	C H 5%	
<b>Latanoprost with timolol</b>					
Eye drops 0.005% with timolol 0.5%	169,555	\$335,719	\$1.9800	C H 5%	
<b>Timolol maleate</b>					
Eye drops 0.25%	176,195	\$85,278	\$0.4840	C H 5%	For products containing BAK, Pharmac reserves the right to list a BAK or preservative free product for a restricted market. Please note that this line item is for non gel-forming drops.
Eye drops 0.5%	200,560	\$100,280	\$0.5000	C H 5%	For products containing BAK, Pharmac reserves the right to list a BAK or preservative free product for a restricted market. Please note that this line item is for non gel-forming drops.
<b>Tropicamide</b>					
Eye drops 0.5%	780	\$1,067	\$1.3680	C H 5%	Preference for a preservative free product. Where a preservative free product is not awarded Pharmac reserves the right to list a preservative free product in addition to this product. Units and unit subsidy expressed as "per ml".
Eye drops 1%	8,535	\$14,123	\$1.6547	C H 5%	Preference for a preservative free product. Where a preservative free product is not awarded Pharmac reserves the right to list a preservative free product in addition to this product. Unit and unit subsidy expressed as "per ml".